Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $12.8 million.

  • Kymera Therapeutics' Capital Expenditures rose 195.77% to $181,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 90.31%. This contributed to the annual value of $12.8 million for FY2024, which is 62.77% down from last year.
  • As of FY2024, Kymera Therapeutics' Capital Expenditures stood at $12.8 million, which was down 62.77% from $34.5 million recorded in FY2023.
  • Kymera Therapeutics' Capital Expenditures' 5-year high stood at $34.5 million during FY2023, with a 5-year trough of $1.6 million in FY2021.
  • Moreover, its 3-year median value for Capital Expenditures was $12.8 million (2024), whereas its average is $16.7 million.
  • In the last 5 years, Kymera Therapeutics' Capital Expenditures surged by 1,609.77% in 2020 and then plummeted by 82.44% in 2021.
  • Kymera Therapeutics' Capital Expenditures (Yearly) stood at $9.1 million in 2020, then crashed by 82.44% to $1.6 million in 2021, then surged by 77.58% to $2.8 million in 2022, then surged by 1,115.80% to $34.5 million in 2023, then plummeted by 62.77% to $12.8 million in 2024.